111 related articles for article (PubMed ID: 28418861)
1. Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor.
Yang ZZ; Li L; Xu MC; Ju HX; Hao M; Gu JK; Jim Wang ZJ; Jiang HD; Yu LS; Zeng S
Oncotarget; 2017 Apr; 8(17):29138-29150. PubMed ID: 28418861
[TBL] [Abstract][Full Text] [Related]
2. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
3. The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ; Li L; Wang L; Yuan LM; Xu MC; Gu JK; Jiang HD; Yu LS; Zeng S
Acta Pharmacol Sin; 2017 Aug; 38(8):1184-1194. PubMed ID: 28552915
[TBL] [Abstract][Full Text] [Related]
4. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.
Stone AN; Mackenzie PI; Galetin A; Houston JB; Miners JO
Drug Metab Dispos; 2003 Sep; 31(9):1086-9. PubMed ID: 12920162
[TBL] [Abstract][Full Text] [Related]
5. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
6. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver.
Mano Y; Usui T; Kamimura H
Drug Metab Dispos; 2007 Jul; 35(7):1182-7. PubMed ID: 17446261
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ
Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode.
Takeda S; Kitajima Y; Ishii Y; Nishimura Y; Mackenzie PI; Oguri K; Yamada H
Drug Metab Dispos; 2006 Aug; 34(8):1277-82. PubMed ID: 16679387
[TBL] [Abstract][Full Text] [Related]
9. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.
Holthe M; Rakvåg TN; Klepstad P; Idle JR; Kaasa S; Krokan HE; Skorpen F
Pharmacogenomics J; 2003; 3(1):17-26. PubMed ID: 12629580
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.
Nakamura A; Nakajima M; Higashi E; Yamanaka H; Yokoi T
Pharmacogenet Genomics; 2008 Aug; 18(8):709-20. PubMed ID: 18622263
[TBL] [Abstract][Full Text] [Related]
11. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
Duguay Y; Báár C; Skorpen F; Guillemette C
Clin Pharmacol Ther; 2004 Mar; 75(3):223-33. PubMed ID: 15001974
[TBL] [Abstract][Full Text] [Related]
12. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
Sawyer MB; Innocenti F; Das S; Cheng C; Ramírez J; Pantle-Fisher FH; Wright C; Badner J; Pei D; Boyett JM; Cook E; Ratain MJ
Clin Pharmacol Ther; 2003 Jun; 73(6):566-74. PubMed ID: 12811366
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of spinal cord gene expression contributes to enhanced postoperative pain and analgesic tolerance subsequent to continuous opioid exposure.
Sahbaie P; Liang DY; Shi XY; Sun Y; Clark JD
Mol Pain; 2016; 12():. PubMed ID: 27094549
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine.
Abildskov K; Weldy P; Garland M
Drug Metab Dispos; 2010 Apr; 38(4):545-53. PubMed ID: 20071451
[TBL] [Abstract][Full Text] [Related]
15. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties.
Ohno S; Kawana K; Nakajin S
Drug Metab Dispos; 2008 Apr; 36(4):688-94. PubMed ID: 18187562
[TBL] [Abstract][Full Text] [Related]
16. Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.
Yuan L; Qian S; Xiao Y; Sun H; Zeng S
Biochem Pharmacol; 2015 May; 95(1):58-70. PubMed ID: 25770680
[TBL] [Abstract][Full Text] [Related]
17. Reverse of Acute and Chronic Morphine Tolerance by Lithocholic Acid
Yang Z; Li L; Hu H; Xu M; Gu J; Wang ZJ; Yu L; Zeng S
Front Pharmacol; 2016; 7():404. PubMed ID: 27847477
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
[TBL] [Abstract][Full Text] [Related]
19. Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain.
Yamada H; Ishii K; Ishii Y; Ieiri I; Nishio S; Morioka T; Oguri K
J Toxicol Sci; 2003 Dec; 28(5):395-401. PubMed ID: 14746343
[TBL] [Abstract][Full Text] [Related]
20. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4.
Takeda S; Ishii Y; Iwanaga M; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
Mol Pharmacol; 2005 Mar; 67(3):665-72. PubMed ID: 15611481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
